

	Month (%)	Quarter (%)	1 Year (%)	2 Years (% p.a.)	3 Years (% p.a.)	Since Inception^ (% p.a.)	Since Inception Cumulative^ (%)
eInvest Better Future Fund (Managed Fund)	6.4	4.3	-4.1	-0.9	12.5	8.1	35.9
S&P/ASX Small Ordinaries Accumulation Index	2.8	-1.7	-9.4	-3.5	9.2	3.2	13.0
Value Added	3.6	6.0	5.3	2.6	3.3	4.9	22.9

^Inception date was 23 May 2019. Performance shown above are net of fees. Fund returns are calculated using net asset value per unit at the start and end of the specified period and do not reflect the brokerage or the bid ask spread that investors incur when buying and selling units on the ASX. Past performance is not a reliable indicator of future performance.

Overview

The Fund was up 6.4% after fees during the month, outperforming the benchmark by 3.6%. The benchmark finished 2.8% higher in April.

Positive contributors to relative performance during April included Telix Pharmaceuticals (+47.1%), Impedimed (+76.2%), 4D Medical (+165.0%) and NIB Holdings (+9.5%).

Negative contributors to relative performance during the month included not held positions in Blackmores, Corporate Travel and Strike Energy, and our holding in PEXA (-1.6%).

eInvest Better Future Fund (Managed Fund)

The aim of IMPQ is to grow the value of your investment over the long term by investing in companies predominantly outside the S&P/ASX Top 50 Index that conduct business taking into account environmental, social and governance (“ESG”) considerations and/or businesses that are making a positive contribution to creating a better future. IMPQ seeks to provide a total return (after fees) that exceeds the S&P/ASX Small Ordinaries Accumulation Index.

Portfolio Manager

Damian Cottier

IMPQ FUM

\$42 million

Distribution Frequency

Annually (if any)

Fees

0.99% p.a. (incl of GST and RITC)
+ Performance fee

Inception Date


23 May 2019

Better Future Highlight

During the month portfolio holding Janison announced that it had successfully delivered the nationwide NAPLAN (“National Assessment Program – Literacy & Numeracy”) assessment. The assessment was delivered fully online across 9,300 participating primary and high schools across Australia. Janison has developed the online assessment platform for NAPLAN over the last seven years in partnership with Education Services Australia and Microsoft. Janison’s platform delivered 4.4 million tests for 1.3 million students over a week. In a peak day, Janison delivered over 1 million tests and 0.3 million students sitting the exam simultaneously on Janison’s platform without issue.


Janison also announced that it had been awarded a global agreement with Oxford University Press (“OUP”) to develop and deliver a range of new and existing assessment products globally. This follows the announcement last year that it had entered into a global partnership with Cambridge University Press & Assessment. OUP is the education publishing arm of Oxford University. The products will be rolled out from 2024 and include tests for years 6 and 9 globally and using the same core Janison technology that has delivered NAPLAN.

Growth of \$100,000 Since Inception



Performance shown net of fees with distributions reinvested. Does not take into account any taxes payable by an investor. Past performance is not a reliable indication of future performance.

Portfolios Contribution to the UN Sustainable Development Goals



Total Contribution: 65.52%
(equal to 52.11% social impact contribution and 13.41% environmental impact contribution)

Fund Review

The Fund was up 6.4% after fees during the month, outperforming the benchmark by 3.6%. The benchmark finished 2.8% higher in April.

Positive contributors to relative performance during April included Telix Pharmaceuticals (+47.1%), Impedimed (+76.2%), 4D Medical (+165.0%) and NIB Holdings (+9.5%).

Negative contributors to relative performance during the month included not held positions in Blackmores, Corporate Travel and Strike Energy, and our holding in PEXA (-1.6%).

Telix Pharmaceuticals announced a better-than-expected quarterly update with revenue exceeding A\$100m in only the company's third full quarter of sales of Illucix. This is the result of Illucix having revolutionised the scanning, and hence management, of prostate cancer. The company also announced its first quarter of positive cashflow even after investing \$27m into research and development. This R&D spend includes the company's Zircon renal cancer imaging product which is currently going through the FDA fast-track approval process and is expected to greatly improve scanning for renal cancer.

Impedimed delivered a quarterly update which indicated the inclusion of the company's SOZO bioimpedance spectroscopy platform in the US National Comprehensive Cancer Network survivorship guidelines had resulted in the company making good progress in reimbursement processes with US health insurers, and it is now expected that these processes are likely to be successful. This could result in a large increase in sales of the SOZO platform which is used to assess lymphoedema risk in breast cancer survivors.

4D Medical made two important announcements. The first was that it had signed its first US hospital contract for the company's XV Lung Ventilation Analysis software with the University of Miami. While the contract is not large it suggests the company is making progress in the US market and physicians see the clinical value of the product across a range of indications including Chronic Obstructive Pulmonary Disease. A key aspect of making further progress in the US is signing similar agreements with Veteran's Affairs hospitals given the number of US veterans with lung disease including from "Burn Pits". To this end the company also announced Dr David Shulkin had been appointed to an advisory role at 4D Medical. Dr Shulkin was previously the Secretary of the United States Department of Veteran Affairs.

Negative relative contributors were largely not held positions in Blackmores, Corporate Travel and Strike Energy. PEXA (held) declined after announcing the resignation of the company's Chief Financial Officer.

At month end, the portfolio held 43 stocks and cash of 8.2%.

At April end, the weighted average Perennial-derived Environmental, Social, Governance and Engagement ("ESGE") Score of the Fund was 7.3 which is 29% higher than the benchmark ESGE Score of 5.6.

ESG Activity

Our ESG activity during the month included:

- Perennial Better Future released its 5 Years of BFT Impact – documenting the impact we have had with our investments over the 5 years since inception. Over the past 5 years, the Better Future team has demonstrated its thought leadership in the ESG investing landscape, through over 90 hours of active participation in industry initiatives including educational webinars, panel presentations, surveys and collaborative industry groups such as Climate Action 100+ and IAST-APAC. Additionally, since inception, the team has conducted over 1,000 meetings with portfolio companies, including over 250 dedicated ESG meetings. The Better Future team believes that company engagement is crucial in helping companies to progress their ESG practices and ultimately, generate improved ESG outcomes. Since inception, 68 female directors have been appointed to the boards of companies held in the Better Future Trust, typically following the team's engagement.
- Discussed with Calix the company's progress in measuring the company's greenhouse gas footprint and setting targets. The process is underway and we expect more disclosure in the 2023 Annual Report.
- Attended a cyber security conference to understand the impact of cloud computing & security and evolving security threats & solutions.
- Attended a meeting on "how to audit a climate report" for deeper knowledge into assessing a company's climate reporting.

Top 5 Portfolio Positions	IMPQ (%)	Index (%)
Telix Pharmaceuticals Ltd	5.2	1.1
Meridian Energy	5.1	0.0
Sims Ltd	4.8	1.1
Chorus Ltd	4.4	1.5
AUB Group Ltd	4.1	1.1



Portfolio Manager, Damian Cottier (right) and Co-Head of ESG & Equities Analyst, Emilie O'Neill (left)

Contact us



Level 27, 88 Phillip Street
Sydney NSW 2000



1300 420 094



invest@perennial.net.au



www.perennial.net.au

Issued by Perennial Value Management Limited (ABN 22 090 879 904, AFSL No. 247293) as the Investment Manager. The Responsible Entity is Perennial Investment Management Limited (ABN 13 108 747 637, AFSL No. 275101). Perennial Partners Limited (ABN 90 612 829 160) is a Corporate Authorised Representative (1293138) of Perennial Value Management Limited. Both the Investment Manager and Responsible Entity form part of Perennial Partners. This promotional statement is provided for information purposes only. Accordingly, reliance should not be placed on this promotional statement as the basis for making an investment, financial or other decision. This promotional statement does not take into account your investment objectives, particular needs or financial situation and is not intended to constitute advertising or advice of any kind and you should not construe the contents of promotional statement as legal, tax, investment or other advice. This promotional statement does not constitute an offer or inducement to engage in an investment activity nor does it form part of any offer documentation, offer or invitation to purchase, sell or subscribe for interests in any type of investment product or service. You should read and consider any relevant offer documentation applicable to any investment product or service and consider obtaining professional investment advice tailored to your specific circumstances before making any investment decision. While every effort has been made to ensure the information in this promotional statement is accurate; its accuracy, reliability or completeness is not guaranteed. Past performance is not a reliable indicator of future performance. Net performance is based on redemption price for the period and assumes that all distributions are reinvested. Fees indicated reflect the maximum applicable. The current relevant product disclosure statement and target market determination can be found on Perennial's website www.perennial.net.au. Use of the information on our website is governed by Australian law and is subject to the terms of use. No distribution of this material will be made in any jurisdiction where such distribution is not authorised or is unlawful.